Evidence map›Paper›PMID 29986896›Full record

ArticleInfection and immunity2018

Standardization of Pneumococcal Biofilm Release to PncO Expression, a Predictive Measurement of Virulence.

A Hill, M Beitelshees, B A Pfeifer, C H Jones

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Involvement of theFrontiers in veterinary science · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

A HillAbcombi Biosciences Inc., Amherst, New York, USA.
M BeitelsheesAbcombi Biosciences Inc., Amherst, New York, USA.
B A PfeiferAbcombi Biosciences Inc., Amherst, New York, USA blainepf@buffalo.edu charles.jones@abcombibio.com.
C H JonesAbcombi Biosciences Inc., Amherst, New York, USA blainepf@buffalo.edu charles.jones@abcombibio.com.
Abcombi Biosciences (United States) · USUniversity at Buffalo, State University of New York · US

Funding

A Hybrid Bio-synthetic Vector Designed to Elicit Directed in vivo Immune ResponseR21AI117309 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PFEIFER, BLAINE A. · 2016 to 2017
$435k
A Hybrid Biomaterial-biological Vector for Antigen Presenting Cell Gene DeliveryR03AI088485 · NIAID · TUFTS UNIVERSITY MEDFORD · PI PFEIFER, BLAINE A. · 2010 to 2011
$145k
NIAID NIH HHS R03 AI088485NIAID NIH HHS R21 AI117309
6 · The paper itself

Abstract

A critical component in clinical trials for vaccines against pneumococcal disease is the establishment of robust preclinical models and clinical correlates of protection, which, in the case of the causative bacterial agent

Indexed as

BiofilmsAntigens, BacterialBacterial ProteinsHumansPneumococcal InfectionsStreptococcus pneumoniaeVirulenceVirulence FactorsAntigens, BacterialBacterial ProteinsVirulence Factorsassay developmentbiofilmspneumococcusvaccines

Identifiers

PMID29986896
PMCPMC6105903
OpenAlexW2830994457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.